

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

26 Feb 2026

### Clinical trial comparing the sedative effect of Dexmedetomidin infusion versus placebo in the intensive care unit on patients undergoing open heart surgery under cardiopulmonary bypass pump.

#### Protocol summary

##### Study aim

compare the efficacy of sedative effect of Dexmedetomidin infusion with placebo in patients undergoing open heart surgery in the intensive care unit

##### Design

In this double blind clinical trial, 60 patients undergoing open heart surgery under a cardiopulmonary bypass pump, were randomly assigned into two groups of Dexmedetomidine and placebo

##### Settings and conduct

In this double blind clinical trial, 60 patients undergoing open heart surgery under a cardiopulmonary bypass pump, who were referred to Baqiyatallah Hospital, were randomly assigned randomly into two groups of Dexmedetomidine (group D) and placebo (group P). The medication is prepared by a collaborator, and the investigator and the patient will not be aware of the type of injectable drug.

##### Participants/Inclusion and exclusion criteria

60 patients undergoing open heart surgery are studied. Emergency patients, patients with liver and renal failure, grade 2 or 3 cardiac block, history of psychiatric disorders, drug addicts and redo surgery are not included in the study.

##### Intervention groups

In the dexmedmotidine group after completing the operation, doses of dexmedetomidine 1µg/ kg infused over 10 minutes and transferred to the ICU and placed under mechanical ventilation. In ICU, low dose infused doses of 0.2 µg / kg will increase, and the dose will increase to 0.7 µg / kg. In placebo group, normal saline is infused within 10 minutes and transferred to ICU and placed under mechanical ventilation. In ICU, placebo infusion continues. In the two groups, the purpose of sedation is until the patient is mechanically ventilated by Richmond agitation sedation scale ( RASS) -2\_ + 1 and after extubation of RASS 0.

##### Main outcome variables

Reduced Delirium, duration of stay in ICU, duration of mechanical ventilation, Dose of midazolam and morphine, incidence of arrhythmia and Increased satisfaction of nurses in the intensive care unit

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20161022030421N4**  
Registration date: **2019-07-16, 1398/04/25**  
Registration timing: **registered\_while\_recruiting**

Last update: **2019-07-16, 1398/04/25**

Update count: **0**

##### Registration date

2019-07-16, 1398/04/25

##### Registrant information

##### Name

Marzieh Lak

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 2244 9013

##### Email address

marziehlak@bmsu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-07-11, 1398/04/20

##### Expected recruitment end date

2019-12-26, 1398/10/05

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Clinical trial comparing the sedative effect of Dexmedetomidin infusion versus placebo in the intensive care unit on patients undergoing open heart surgery under cardiopulmonary bypass pump.

**Public title**

The effect of Dexmedetomidin infusion in the intensive care unit

**Purpose**

Health service research

**Inclusion/Exclusion criteria****Inclusion criteria:**

Patients referred for coronary artery bypass grafting after obtaining informed consent

**Exclusion criteria:**

Emergency patients Has a history of liver disease, kidney disease, heart block grade 2 or 3 Systolic blood pressure below 90 mmHg History of psychological disease Use of psychological drugs Opioid addiction Re- surgery

**Age**

No age limit

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

**Sample size**

Target sample size: 60

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Randomization was stratified using a random table number

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

The medication or placebo is prepared and coded by the co-worker in a 50cc syringe. Each cc of the solution in the syringe contains four micrograms of Dexmedetomidine or a placebo. The patient and the researcher and the specialist nurses will not be informed of the prepared syringe's contents. Researcher will be injected into a patient for 10 minutes from a randomized encoded syringe, equivalent to 1 µg / kg Dexmedetomidine and then the medicine will be infused in a volume equivalent to 0.2 to 0.7 micrograms per kilogram, in accordance with the patient's needs. Upon

completion of the sampling, the co-worker will provide the information about the coding of the syringes.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee of Baqiyatallah University of Medical Sciences

**Street address**

Baqiyatallah University of Medical Science, Mollasadra Street, Sheikh Bahaee Street, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1435917541

**Approval date**

2019-06-25, 1398/04/04

**Ethics committee reference number**

IR.BMSU.REC.1398.090

**Health conditions studied****1****Description of health condition studied**

Patients undergoing heart surgery with CPP pump.

**ICD-10 code**

I25.1

**ICD-10 code description**

Atherosclerotic heart disease of native coronary artery

**Primary outcomes****1****Description**

Incidence of delirium

**Timepoint**

From the arrival of the patient to the intensive care unit until the patient's discharge from the intensive care unit, the nurse will be evaluated in each shift.

**Method of measurement**

Confusion assessment method for the ICU (CAM-ICU ).

**2****Description**

Duration of stay in the intensive care unit

### **Timepoint**

From the arrival of the patient to the intensive care unit until the discharge of the patient from the intensive care unit is evaluated by the unit of the day.

### **Method of measurement**

From the arrival of the patient to the intensive care unit until the discharge of the patient from the intensive care unit is evaluated by the unit of the day.

### **3**

#### **Description**

Duration of mechanical ventilation

#### **Timepoint**

From the patient's arrival to the intensive care unit until the tracheal tube is removed, in hours

#### **Method of measurement**

From the patient's arrival to the intensive care unit until the tracheal tube is removed, in hours

### **4**

#### **Description**

Reducing the dose required by morphine and midazolam to achieve desired urination

#### **Timepoint**

The patient's arrival in the intensive care unit until the patient's discharge from the intensive care unit is calculated in milligrams.

#### **Method of measurement**

The patient's arrival in the intensive care unit until the patient's discharge from the intensive care unit is calculated in milligrams.

### **5**

#### **Description**

Incidence of arrhythmia

#### **Timepoint**

From the patient's entrance to the intensive care unit until the discharge of the patient from the intensive care unit is assessed by continuous monitoring of electrocardiogram by a specialist nurse.

#### **Method of measurement**

From the patient's entrance to the intensive care unit until the discharge of the patient from the intensive care unit is assessed by continuous monitoring of electrocardiogram by a specialist nurse.

### **6**

#### **Description**

Assessment of Nurses' satisfaction in ICU

#### **Timepoint**

During the period of hospital stay in the intensive care unit by three specialist nurses, using VAS score

#### **Method of measurement**

During the period of hospital stay in the intensive care unit by three specialist nurses, using VAS score

## **Secondary outcomes**

### **1**

#### **Description**

Changes in blood pressure

#### **Timepoint**

From the beginning of the patient's arrival in the intensive care unit until the first six hours, blood pressure was recorded every hour. Then from the sixth hour until the discharge of the patient from the intensive care unit was recorded every 3 hours.

#### **Method of measurement**

From the beginning of the patient's arrival in the intensive care unit until the first six hours, blood pressure was recorded every hour. Then from the sixth hour until the discharge of the patient from the intensive care unit was recorded every 3 hours.

### **2**

#### **Description**

Heart rate

#### **Timepoint**

From the beginning of the patient's arrival in the intensive care unit until the discharge of the patient from the intensive care unit, heart rate was continuously monitored and recorded.

#### **Method of measurement**

From the beginning of the patient's arrival in the intensive care unit until the discharge of the patient from the intensive care unit, heart rate was continuously monitored and recorded.

## **Intervention groups**

### **1**

#### **Description**

Intervention group: Dexmedetomidine is infused at a dose of 1 µg / kg for 10 minutes and the patient is transferred to the ICU and placed under mechanical ventilation. In ICU, a low dose infusion of 0.2 µg / kg of infusion begins, and, according to the patient's need, the dosage of the drug increases to 0.7 µg / kg for the purpose of achieving Richmond agitation-sedation scale 1-2 + 1. After the extubation condition, the patient is extubated and the dosage of Dexmedetomidine is continued with the aim of achieving RASS 0 (calm and alert).

#### **Category**

Treatment - Drugs

### **2**

#### **Description**

Control group: after the completion of surgery, placebo (normal saline) is infused over 10 minutes (due to the blindness of the study), and the patient is transferred to the ICU and placed under mechanical ventilation. ICU will find a placebo infusion. In this group, the purpose of sedation is until the patient is mechanically ventilated by RASS -2\_ + 1 and after extruding RASS 0.

#### **Category**

Placebo

## Recruitment centers

### 1

#### Recruitment center

**Name of recruitment center**

Baqiyatallah hospital

**Full name of responsible person**

Marzieh Lak

**Street address**

Baqiyatallah University of Medical Science, Mollasadra Street, Sheikh Bahae Street, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1435917541

**Phone**

+98 21 2244 9013

**Email**

marziehlak@bmsu.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**

Bagheiat-allah University of Medical Sciences

**Full name of responsible person**

Mohammad Hasan Kalantar

**Street address**

Baqiyatallah University of Medical Science, Mollasadra Street, Sheikhbahai Street, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1435915371

**Phone**

+98 21 8126 3395

**Email**

k-motamedi@hotmail.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Bagheiat-allah University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

#### Contact

**Name of organization / entity**

Bagheiat-allah University of Medical Sciences

**Full name of responsible person**

Marzieh Lak

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Baqiyatallah University of Medical Science, Mollasadra Street, Sheikhbahai Street, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1435915371

**Phone**

+98 212449013

**Email**

marziehlak@bmsu.ac.ir

## Person responsible for scientific inquiries

#### Contact

**Name of organization / entity**

Bagheiat-allah University of Medical Sciences

**Full name of responsible person**

Marzieh Lak

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Baqiyatallah University of Medical Science, Mollasadra Street, Sheikhebahahi Street, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1435915371

**Phone**

+98 212449013

**Email**

marziehlak@bmsu.ac.ir

## Person responsible for updating data

#### Contact

**Name of organization / entity**

Bagheiat-allah University of Medical Sciences

**Full name of responsible person**

Marzieh Lak

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Baqiyatallah University of Medical Science, Mollasadra Street, Sheikhbahai Street, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1435915371

**Phone**

+98 212449013

**Email**

marziehlak@bmsu.ac.ir

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Not applicable

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Not applicable

**Data Dictionary**

Not applicable

**Title and more details about the data/document**

all collected deidentified IPD

**When the data will become available and for how long**

starting 1 months after publication

**To whom data/document is available**

people working in academic institutions

**Under which criteria data/document could be used**

for meta analysis

**From where data/document is obtainable**

from Email

**What processes are involved for a request to access data/document**

By sending a request to the university Vice-Dean for Research and obtaining a license

**Comments**